High-risk (HR) multiple myeloma (MM) is a subgroup of MM patients that is variably defined. Patients with 17p deletion are considered HR and their optimal treatment approach has not been determined. Various strategies have been suggested to improve outcomes in MM patients harboring del 17p, including tandem transplantation. Evaluate the outcomes of multiple myeloma patients harboring 17p deletion that underwent autologous stem cell transplants (ASCT). Retrospective study. Referral center in the US (Mayo Clinic). 116 MM patients with 17p deletion that underwent ASCT at Mayo Clinic. Patients were defined as 17p-deleted if they met the following criteria: If 50 cells in the bone marrow sample and 10 abnormal cells with the deletion were identified (20%) or if the bone marrow sample had between 20-50 total cells and 20% abnormal cells with the deletion were identified. We excluded patients that relapsed prior to ASCT, patients that underwent ASCT more than 12 months from the diagnosis, and patients that underwent tandem ASCT. PFS, OS. There was no difference in the OS or PFS between patients that received VRd (bortezomib, lenalidomide, and dexamethasone) versus VCd (bortezomib, cyclophosphamide, and dexamethasone) induction. There was no OS or PFS difference between immunomodulatory drug (IMiD)-based and proteasome inhibitor (PI)-based maintenance, but there was a PFS advantage to patients that received combined maintenance (includes two novel agents). The OS and PFS of the entire cohort were NR and 29 months, respectively, similar to the outcomes in the single transplant arm in 17p-deleted patients that were recently published (EMNO2/HO95). The outcomes of our patients were similar to that of the single-arm ASCT in the EMN02 trial, and no difference in outcomes were found between patients that received VRd and VCd inductions, suggesting that tandem transplants may be considered for 17p-deleted MM patients treated with VRd induction. Dual novel agent maintenance therapy is important in improving outcome.